Lymphoma-targeted treatment using a folic acid-decorated vincristine-loaded drug delivery system
Authors Qiu L, Dong C, Kan X
Received 23 September 2017
Accepted for publication 12 February 2018
Published 17 April 2018 Volume 2018:12 Pages 863—872
Checked for plagiarism Yes
Review by Single-blind
Peer reviewers approved by Dr Rammohan Devulapally
Peer reviewer comments 2
Editor who approved publication: Dr Sukesh Voruganti
Lei Qiu,1 Chao Dong,2 Xuan Kan3
1Department of Internal Medicine Oncology, Shandong Cancer Hospital Affiliated to Shandong University, Shandong Academy of Medical Science, Ji’nan, Shandong Province, People’s Republic of China; 2Department of Oncology, 105 Hospital of People’s Liberation Army, Heifei, Anhui Province, People’s Republic of China; 3Department of Oncology, Hospital of Traditional Chinese Medicine of Laiwu City, Laiwu, Shandong Province, People’s Republic of China
Purpose: B-cell lymphoma is the most frequently diagnosed lymphoid tumor. Folic acid (FA)-decorated systems were found to be preferentially internalized on the B-cell lymphoma cell line which is reported to express the folate receptor. This study was designed to develop an FA-decorated vincristine (VCR)-loaded system for targeted lymphoma treatment.
Methods: FA-decorated lipid was synthesized. VCR-loaded lipid-polymer hybrid nanoparticles (LPNs) were fabricated. In vitro cell lines and an in vivo lymphoma animal model was used to evaluate the anti B-cell lymphoma effect.
Results: FA-decorated, VCR-loaded LPNs (FA-VCR/LPNs) have shown a targeted effect in delivery to B-cell lymphoma cells. FA-VCR/LPNs also showed the highest anti-tumor effect in murine-bearing lymphoma xenografts.
Conclusion: FA-VCR/LPNs can achieve targeted delivery of VCR, bring about an outstanding therapeutic effect to treat lymphoma, and also reduce the systemic toxicity. FA-VCR/LPNs could be an excellent system for lymphoma therapy.
Keywords: lymphoma, drug delivery system, lipid-polymer hybrid nanoparticles, folic acid, vincristine
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]